Ignite Creation Date:
2025-12-18 @ 6:17 AM
Ignite Modification Date:
2025-12-23 @ 10:30 PM
Study NCT ID:
NCT00751452
Status:
None
Last Update Posted:
2011-01-19 00:00:00
First Post:
2008-09-09 00:00:00
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Citrulline Allo. Evaluation of Citrullinemia as a Marker of Bowel Damage After Allogeneic Bone Marrow Transplantation in Children
Sponsor:
None
Organization:
Study Overview
Official Title:
Evaluation of Citrullinemia as a Marker of Bowel Damage After Allogeneic Bone Marrow Transplantation in Children
Status:
None
Status Verified Date:
2011-01
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
30 children included. Dosage of citrullinemia on day -7, day 0 and every week up to 100 days after BMT. Histological examination and extensive infectious screening in case of persistent digestive symptoms (more than 3 days).
Two groups of patients regarding on digestive involvement. Comparison of the values of citrullinemia between these two groups.
Two groups of patients regarding on digestive involvement. Comparison of the values of citrullinemia between these two groups.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: